Login
Navigate Fool.com
Will DRTX beat
the market?

Durata Therapeutics

NASDAQ: DRTX

Community Rating: 4 Stars: Favorite

12.67 -0.11 (-0.86%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $12.79
Previous Close $12.78
Daily Range $12.58 - $13.09
52-Week Range $6.65 - $16.99
Market Cap $337.5M
P/E Ratio -4.97
Dividend (Yield) $0.00 (0.0%)
Volume 182,767
Average Daily Volume 536,716
Current FY EPS -$2.28

How do you think DRTX
will perform against the market?

Top DRTX Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Pfizer Blockbuster Zyvox Under Attack

Incoming competition for Pfizer's $1.4 billion Zyvox market is threatening on multiple fronts.

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?

Two drugs are hot on Pfizer’s tail.

Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp

Today's top stories in biotech and health care.

3 Upcoming FDA Meetings You Should be Watching

With three FDA panel meetings to close out the month investors should have their eyes on these three companies.

Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.

Cubist Pharmaceuticals and Durata Therapeutics both have antibiotics scheduled for regulatory review with the FDA later this month. Which company offers investors the better risk to reward profile?

3 Biotechs With Major Catalysts Incoming

FDA advisory committees might determine the future for Exact Sciences, Durata Therapeutics, and MannKind Corporation beginning at the end of March.

5 Reasons to Buy PDL BioPharma Inc

PDL BioPharma will extend its operations beyond 2014. I believe there are 5 reasons the stock is now a buy.

Morning Movers in Biotech: AstraZeneca PLC, Durata Therapeutics, Inc. and Intercept Pharmaceuticals,

Today's top stories in healthcare and biotechnology.

3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata

A video looking at upcoming FDA decisions for Chelsea Therapeutics, MannKind, and Durata Therapeutics.

Why Durata Therapeutics Inc. Shares Marched Higher

Durata shares soar after the FDA grants its key experimental drug a priority review. Can Durata shares head even higher now?

See More DRTX News...

Sector

Healthcare

Industry

Drugs

Durata Therapeutics (DRTX) Description

Durata Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Website: http://www.duratatherapeutics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks